Zhejiang Hisoar Stock Soars 4.69%, Hits Intraday High of CNY 8.25

Zhejiang Hisoar Pharmaceutical Co., Ltd. has experienced a notable increase of 4.69% on February 25, 2026, reaching an intraday high of CNY 8.25. This performance stands in contrast to the broader market, as the China Shanghai Composite index declined by 1.26% on the same day. Over the past week, the stock has shown a robust gain of 7.35%, significantly outperforming the composite index, which rose by only 0.41%. In terms of longer-term performance, Zhejiang Hisoar has achieved a remarkable 68.34% increase over the past year, compared to the China Shanghai Composite's 22.49% gain. Year-to-date, the stock has risen by 28.69%, again surpassing the composite's 2.85% performance. Despite these positive short-term trends, the company faces challenges, including a low Return on Capital Employed (ROCE) of 2.16% and a concerning debt-equity ratio of 0.01. The pharmaceutical and biotechnology sector remains competitive, and Zhejiang Hisoar's market position will be closely monitored as it navigates these dynamics.